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Abstract
Background: Studies indicate that acquired deficits negatively affect patients’ self-reported health related quality of life
(HRQOL) and survival, but the impact of HRQOL deterioration after surgery on survival has not been explored.
Objective: Assess if change in HRQOL after surgery is a predictor for survival in patients with glioblastoma.
Methods: Sixty-one patients with glioblastoma were included. The majority of patients (n=56, 91.8%) were operated using
a neuronavigation system which utilizes 3D preoperative MRI and updated intraoperative 3D ultrasound volumes to guide
resection. HRQOL was assessed using EuroQol 5D (EQ-5D), a generic instrument. HRQOL data were collected 1–3 days
preoperatively and after 6 weeks. The mean change in EQ-5D index was 20.05 (95% CI 20.15–0.05) 6 weeks after surgery
(p=0.285). There were 30 patients (49.2%) reporting deterioration 6 weeks after surgery. In a Cox multivariate survival
analysis we evaluated deterioration in HRQOL after surgery together with established risk factors (age, preoperative
condition, radiotherapy, temozolomide and extent of resection).
Results: There were significant independent associations between survival and use of temozolomide (HR 0.30, p=0.019),
radiotherapy (HR 0.26, p=0.030), and deterioration in HRQOL after surgery (HR 2.02, p=0.045). Inclusion of surgically
acquired deficits in the model did not alter the conclusion.
Conclusion: Early deterioration in HRQOL after surgery is independently and markedly associated with impaired survival in
patients with glioblastoma. Deterioration in patient reported HRQOL after surgery is a meaningful outcome in surgical
neuro-oncology, as the measure reflects both the burden of symptoms and treatment hazards and is linked to overall
survival.
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Introduction
Surgical studies in patients with glioblastoma have focused
much on resection grades and maximal safe resection is usually
advocated. However, measurements of both extents of resection
and safety vary between studies and there are few controlled trials.
Due to non-uniform inclusion criteria and assessments of
outcomes, direct comparison of results and techniques are difficult,
if not impossible [1]. Nevertheless, it seems like resections need to
be extensive to improve survival, but the resection grade threshold
for a probable clinical benefit remains debated [2–4]. Safety is less
often assessed and there is no uniform and accepted method for
reporting of adverse events in surgical trials [5]. Often clinicians or
operating surgeons report clinical outcomes in gross functional
scales with a potential of assessment and interest bias.
The combination of this ultimately fatal disease with the delicate
balance between potential effect and hazards of surgery makes
patients’ perioperative HRQOL of particular interest. However,
the impact of glioblastoma surgery on patient reported outcomes
has not been explored much [6]. We have earlier described
possible predictors of HRQOL in patients undergoing glioma
surgery. The study clearly demonstrated the devastating effect of
acquired deficits on patient reported HRQOL [7]. A recent paper
found that surgical acquired deficits may be associated with
decreased survival as well [8], but the possible impact of
postoperative loss of HRQOL on survival has not been explored.
In the present prospective study we aimed to assess if changes in
HRQOL after surgery added any prognostic information to the
already established risk factors.
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Ethics statement
All patients included have given their written and informed
consent. The Data Inspectorate in Norway approved registration
and management of data. The study was approved by the
Regional Ethical Committee for Health Region Mid-Norway.
Methods
Study subjects were recruited from patients aged $18 years
admitted to our department for scheduled brain tumor surgery, in
the period from January 2007 through December 2010. Patients
were followed until death or until May 15
th, 2011. Survival was
calculated from the date of surgery. Only patients with
histopathological confirmed glioblastoma according to the WHO
classification were included in this study. Patients provided written
informed consent and filled out the EuroQol 5D (EQ-5D)
questionnaire 1–3 days before surgery. A study nurse scored
preoperative Karnofsky Performance Status (KPS) on admission.
Patient follow-up by a study nurse was scheduled at 6 weeks
(median time to follow up: 47 days) after surgery. We decided to
use 6 weeks to allow for some recovery from transient surgically
induced deficits. In addition, few patients experience significant
tumor progression in this time frame. At this time point some
patients may have started adjuvant therapy and this could
influence the HRQOL, however this is expected to be the same
between the groups and therefore unlikely to influence the results.
Adverse effects are also quite rare during the initiating phase of
adjuvant radiotherapy and/or concomitant temozolomide treat-
ment. Structured interviews were used to assess HRQOL (EQ-5D)
using the same questionnaire as preoperatively. The patients were
also interviewed about possible complications, acquired and/or
worsened deficits (motor, language, vision, unsteadiness and other)
and altered mental functions (memory, personality and other)
experienced after the procedure. Only patients with complete
HRQOL data were included in the analyses. Tumor volumes and
resection grades were determined from preoperative and early
postoperative MRI volumes using an ellipsoid model (4 6r
3/3), as
described by others [9]. Gross total resection (GTR) was defined as
no visible contrast enhancing tumor tissue on the early
(,72 hours) postoperative 1.5 T or 3.0 T MRI scans.
Study population
Sixty-seven patients with glioblastoma were included from
baseline, but 6 (9.0%) patients did not complete the EQ-5D
questionnaire after surgery. All patients who did not respond were
dead at last follow-up. Three were lost to follow-up as they were
already dead or in a terminal condition at 6 weeks, whereas the
other three patients who were lost to follow- up lived for a median
30 weeks. The only in-hospital registered complication among
these six patients was seizures in one patient who had no seizures
preoperatively. Median preoperative HRQOL for these six
patients was 0.59 (range 0.27–0.74).
Sixty-one patients had complete EQ-5D forms before and after
surgery and were included in the analyses. Clinical characteristics
are presented in Table 1. The mean age of included patients was
58 years (range 26–81) and 29 (47.5%) were female. The median
preoperative KPS was 80 and 84.7% were functionally indepen-
dent (KPS 70–100). Thirty eight (62.3%) of the operations were
primary and 23 (37.7%) were reoperations.
Surgical procedure
All operations were performed under general anesthesia. The
SonoWandH neuronavigation system was available if requested by
the surgeon and was used in 56 (91.8%) of the operations. The
system utilizes 3D preoperative MRI and updated intraoperative
3D ultrasound volumes to guide resection [10]. In eloquent lesions
functional neuronavigation was incorporated utilizing a method
described in detail earlier [11,12]. Functional MRI and diffusion
tensor imaging data was incorporated into the system in 19
(31.1%) and 23 (37.7%) of the operations respectively. Sixty
(98.4%) of the 61 included patients underwent craniotomy and
tumor resection. One patient underwent biopsy only. The median
preoperative tumor volume was 18.4 cm
3 and the median
resection grade was 96.3% with GTR achieved in 24 (39.3%) of
the patients.
The EuroQol 5D
EQ-5D is a generic (not developed for any specific patient
group) and preference-weighted measure of HRQOL [13]. The
questionnaire has been applied to a wide range of health
conditions and treatments as well as population based health
surveys [14,15]. There are many different instruments available
for researchers interested in assessing HRQOL. We chose to use
EQ-5D due to the simplicity of the instrument, to enhance patient
perception and perhaps also compliance. Generic instruments
such as EQ-5D lack disease specific questions that may be relevant
to the patient group (e.g. cognitive functions). Generic instruments
may therefore lack sensitivity to measure small benefits or negative
consequences of surgery. However, we have earlier demonstrated
that EQ-5D shows good correlation to KPS in patients with
gliomas and is responsive to new neurological deficit which is
highly relevant in this patient group. Also, compared to KPS it
offers a more nuanced picture with respect to change after surgery.
Since KPS only measures one physical dimension of HRQOL it is
insensitive to changes in other dimensions [7]. Another important
difference between EQ-5D and KPS is that the latter most often is
reported by the physician whereas the former is a patient reported
outcome. The EQ-5D has been validated in a Norwegian normal
population [16], but so far not in glioma patients. In EQ-5D, five
dimensions of HRQOL are scored; mobility, self-care, usual
activities, pain/discomfort and anxiety/depression with 3 possible
answers to each dimension, i.e ‘no problem’, slight problem’ or
‘major problem’. This results in the 243 different possible health
Table 1. Clinical characteristics of the patient population.
Clinical characteristics No. (%)
Age (mean, range) 58 years (28–81)
Female 29 (47.5)
Preoperative KPS
a (median, range) 80 (50–100)
Assumed eloquent
b 33 (54.1)
Primary operation 38 (62.3)
Tumor volume (median, range) 18.4 cm
3 (1.1–233.5)
Gross total resection 24 (39.3)
Radiotherapy (now or prior) 56 (91.8)
Temozolomide (now or prior) 46 (75.4)
Acquired neurological deficits 23 (37.7)
Complications 15 (24.6)
Complications leading to reoperation 2 (3.3)
aKPS, Karnofsky Performance Status.
bEloquence is here defined as grade II and grade III according to the definition
by Sawaya et al. [37].
doi:10.1371/journal.pone.0028592.t001
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large survey in the UK population [17]. EQ-5D index value is
from 20.594 to 1, where 1 corresponds to perfect health, and 0 to
death. Negative values are considered to be worse than death. To
provide examples a patient scoring 2, 1, 1, 1, and 2 receives a score
of 0.78, while a patient scoring 2, 3, 3, 2 and 2 receives a score of
0.08. A visual analogue scale where patients rate their current
health state on a line ranging from 0–100 (worst to best imaginable
health) forms the second part of the EuroQol questionnaire. In this
study only the index value was assessed.
Statistics
All analyses were done with the PASW statistics, version 18.0.
Statistical significance level was set to P,0.05. Q-Q plots were
used to test for normal distribution of data. Central tendencies are
presented as means if data is normally distributed and as medians
when skewed. When analyzing changes in EQ-5D (e.g. before and
after surgery) paired sample t-test was used. For comparison of
groups with skewed distribution we utilized Mann-Whitney U test.
For binominal data we used Pearson’s chi square test.
In the Cox multivariate survival analysis the variables were
chosen on the basis of current evidence. The most consistent factors
affecting survival in patients with glioblastoma are age [18] and
preoperative functional status, usually evaluated with Karnofsky
Performance Status (KPS) [19,20]. High quality evidence for the
efficacy for adjuvant treatment with radiotherapy and temozolo-
mide in selected patients is now available [21,22]. There is also
growing evidence suggesting that achieving gross total resection
improves survival [2,23]. We performed univariate analyses for
each risk factor and included all in the multivariate model. The Cox
multivariate model included the following variables: Age (linear),
extent of resection (linear), radiation (yes, no), temozolomide (yes,
no), preoperative Karnofsky (linear) and deterioration in patient
reported HRQOL (yes/no). We are aware that use of linear data is
preferable for statistical reasons (no loss of information), but
dichotomizing variables makes clinical interpretation easier,
especially when scores consist of several summarized variables,
making the immediate interpretation of a number less intuitive. For
radiation and temozolomide ‘‘yes’’ indicates that the treatment has
been provided at any time during the course of the disease.
Results
HRQOL evaluated with EQ-5D
The mean preoperative EQ-5D index was 0.67 compared to
0.62 postoperatively. The mean decline of 20.05 (95% CI 20.15–
0.05) is a non-significant change (p=0.285). There was a wide
range in the difference (20.96 to 0.87) after surgery. There were
30 patients (49.2%) who reported a deterioration 6 weeks after
surgery while 9 (14.8%) were unchanged and 22 (36.1%) reported
improved HRQOL. Treatment and outcome characteristics
comparing the patients with deterioration in HRQOL with the
others are presented in Table 2. Patients who reported
deterioration in HRQOL had EQ-5D index 0.41 postoperatively
as compared to 0.81 in their counterparts (p,0.001). The group of
patients who experienced a deterioration in HRQOL after surgery
(n=30) more often had acquired deficits (p=0.017). There was
also a trend for better HRQOL preoperatively (p=0.051),
although not statistically significant.
Survival
At the end of follow up 22 patients (36%) were still alive.
Median survival was 64 weeks (95% CI 44–84) and a survival
curve is presented in Figure 1.
In a Cox multivariate survival analysis we evaluated the impact
of the established risk factors together with deterioration in
HRQOL. The results are presented in Table 3 and Figure 2A, 2B
and 2C. There were independent associations between survival
and use of temozolomide (HR 0.30, p=0.019, Figure 2A),
radiation therapy (HR 0.26, p=0.030, Figure 2B), and deterio-
ration in HRQOL after surgery (HR 2.02, p=0.045, Figure 2C).
Patients with deterioration in HRQOL more often died during the
first six months following surgery (TYable 2, p=0.017). Preoper-
ative KPS or surgical extent of resection did not reach statistical
significance. Using KPS as a dichotomous variable (KPS$70) or
categorical values for extent of resection (gross total, subtotal and
biopsy) did not change the conclusion. Inclusion of surgically
acquired deficits in the model did not alter the conclusion either,
and actually strengthened the association between deterioration in
HRQOL after surgery with overall survival (HR 2.4, p=0.022).
Since requested in the review process, primary and redo
operations were analyzed separately. Ad-hoc testing verified that
temozolomide and radiation therapy were statistically significant
predictors (p,0.05) when the 38 primary operations were
analyzed separately. Deterioration in HRQOL did not reach
statistical significance (HR 2.9, p=0.05). No statistically significant
predictor was found when analyzing the 23 reoperations
separately.
Discussion
In this prospective follow-up study of 61 glioblastoma patients
we found that deterioration in HRQOL early after surgery seems
to be an independent negative prognostic factor for survival.
Deterioration in HRQOL occurs in about half of the patients
despite the use of modern image guided surgery. The effect of
deteriorating HRQOL was independent of the established risk
factors, such as age, extent of resection, preoperative functional
status (KPS), and adjuvant treatment. The difference in survival
appears to be due to a difference in early mortality. A decline in
HRQOL in the early postoperative phase may be suggestive a
rapidly growing lesion or perhaps negative effects from surgery. It
has been reported that acquired deficits can be associated with
both suboptimal adjuvant therapy [5] and reduced survival [8].
Still, we found that the negative impact of lost HRQOL remained
significant after adjustment for reported acquired neurologic
deficits. Our findings indicate that evaluation of the patients’
perception of own health may be of high prognostic value. If so,
this may allow for new and interesting outcome measures in
glioblastoma surgery that reflect the biology of the disease, the tolls
and the benefits from surgery, while maintaining the relevance for
overall survival. HRQOL measures allow for comparisons across
studies and techniques while avoiding the potential bias associated
with surgeons’ evaluation of own results.
Overall survival is considered the gold standard when
evaluating treatment of glioblastoma and its role is indisputable.
However as survival benefits from surgery can be modest, survival
as study end-point may require multicentre inclusion and years of
recruitment to avoid a statistical power shortage, as experienced in
the 5-ALA study [9]. Further, this measure can be quite unspecific
in a surgical setting as it reflects the results from non-surgical
interventions as well. Progression free survival (PFS) may be used
instead as in the 5-ALA-study [9], but the definitions vary and
interpretation is problematic [24]. Pseudoprogression occurs in
approximately 20% and this makes a pure imaging based outcome
unreliable [25]. There may be contrast enhancement due to the
treatment itself which can be impossible to distinguish from
recurrent disease [24]. Another problem is pseudoresponses, seen
Survival after Postoperative Loss of Health
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enhancement is not necessarily related a clinical response [24,26].
However, the dynamics of tumor progression, the speed of growth,
and patterns of growth may be of prognostic importance if a
reliable measure becomes available.
Extensive resections are advocated by numerous studies due to
the association with improved survival. The association seems
logical, but it is difficult to differentiate the efficacy of treatments
from treatment selection as most studies are neither randomized,
controlled nor prospective [4,23,27]. As mentioned earlier,
differences in patient selection are obstacles for meaningful
comparisons between institutions and techniques. Lastly, with
the exception of the 5-ALA study [9] most studies are not even
designed to evaluate the efficacy of surgical treatment. The present
study does not indicate that extensive resection negatively affects
HRQOL in itself, but it indicates that there is serious potential for
harm in surgical treatment of glioblastomas. We believe careful
therapeutic considerations should be made in cases where safe
gross total resection seems unlikely as the risk might outweigh the
benefit.
These common end-points all have drawbacks which can be
problematic for meaningful clinical interpretation. Since the
prognosis with respect to survival remains unfavorable despite
maximal therapeutic efforts, measuring patients’ quality of survival
is an important supplement [6]. We believe HRQOL adds useful
information both for clinical use and research. Met with the
individual patients, neurosurgeons should take into account the
potential hazards of surgery on patients’ HRQOL and carefully
weigh this up against the likelihood of a survival benefit. Perhaps
the patients’ subjective HRQOL reflects the dynamics of their
disease of prognostic importance, although difficult to quantify
even in serial MRI scans. HRQOL reflects both the burden of
treatment and the severity of the disease and together with the
association to overall we believe that deterioration in HRQOL, or
deterioration free survival after surgery, can be a meaningful
endpoint in surgical trials in neuro-oncology.
In demonstrating prognostic potential of self reported HRQOL
we are in line with earlier studies [28–31]. However, we are not
aware of any other study assessing the prognostic effect of
HRQOL where baseline scores are collected preoperatively.
Other neuro-oncological studies evaluating HRQOL and survival
are usually in the setting of medical clinical trials using initiation of
chemotherapy or radiotherapy as baseline [29–32]. This neglects
Table 2. Comparisons of treatment related factors and outcome among patients experiencing deterioration in HRQOL after
surgery with patients with equal or better HRQOL after surgery.
a
Deterioration in HRQOL
(n=30) Equal or improved HRQOL (n=31) P-value
Primary operation
b 17 (56.6%) 21 (67.7%) 0.375
KPS (median) preop
c 80 90 0.586
Tumor volume (median)
c 24.1 cm
3 15.9 cm
3 0.322
Extent of resection (median)
c 95.1% 96.5% 0.715
Gross total resection
b 11 (36.7%) 13 (41.2%) 0.532
Complication
b 8 (26.7%) 7 (22.6%) 0.401
New/worse deficit
b 16 (53.3%) 7 (22.6%) 0.017
EQ-5D index (mean) preop
d 0.75 0.59 0.051
EQ-5D index (mean) postop
d 0.41 0.81 ,0.001
Deaths in month 0–6
b 11 (36.7%) 3 (9.7%) 0.012
Deaths in month 7–12
b 6 (20.0%) 5 (16.1%) 0.694
Deaths .12 months
b 6 (20.0%) 8 (25.8%) 0.590
Total deaths in follow up
b 23 (76.7%) 16 (51.6%) 0.042
aHRQOL, health related quality of life; KPS, Karnofsky Performance Status; p,0.05 is considered significant.
bPearson chi-square.
cMann-Whitney U test.
dIndependent sample t-test.
doi:10.1371/journal.pone.0028592.t002
Figure 1. Overall survival in the cohort (n=61) presented in a
survival plot.
doi:10.1371/journal.pone.0028592.g001
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the most invasive form of treatment in patients with glioblastoma.
Patients may perceive their health and HRQOL differently with
regards to sex, tumor location and histopathology [6,7]. Therefore
it is difficult to find an optimal cut-off-value with clinical
significance, and searching for a so called ‘‘best cut-off’’ may be
somewhat dubious and increase the risk for false positive findings
[33]. Utilizing changes instead of absolute values seems clinically
more useful in individual patients. This approach takes individual
differences into consideration as patients are their own controls.
This approach may reduce the problems mentioned above.
However, interpreting changes in HRQOL is not necessarily
straightforward. Changes should be evaluated as clinically
meaningful rather than simply statistically significant. This can
be achieved by anchoring HRQOL to therapy, changes with
disease progression or life events [34].
EQ-5D, a generic HRQOL measure, shows good correlation
with traditional outcome measures [7], and in this study it also
demonstrates an association with hard clinical end-points. Thus it
is seemingly a valuable tool in assessing HRQOL in patients with
glioblastoma. Despite potential shortcomings of generic instru-
ments, we are convinced that patient related outcomes with a
validated questionnaire are interesting, valuable, and perhaps less
biased adjuncts to traditional physician rated outcome measures.
The use of EQ-5D for the entire glioblastoma patient population
should be subject of further studies i.e. defining minimal important
change or measuring HRQOL at multiple time points to better
understand the HRQOL throughout the course of the disease.
However, we would insist on using a preoperative evaluation as
baseline to avoid loss of important information.
The relative high number of complications and acquired deficits
in our patients are most likely explained by the assessment method
used. All adverse events were patient reported, including
uncommon outcome parameters used in the neurosurgical
literature, namely memory difficulties, unsteadiness and personal-
ity changes. When using a more common method of assessment
we have reported complications in 21% and deteriorated
functional outcome in 13% in a consecutive, unselected series in
patients with high grade gliomas [1]. Comparing adverse events
between studies is difficult due to different inclusion criteria and
the lack of a standardized way of reporting [5]. With this in mind
we believe these findings are comparable to a large study where
34% of patients experienced perioperative complications and
9.9% displayed worsened neurological status within 3 weeks after
primary craniotomy for malignant glioma [35]. For the future we
would encourage researches to use one standard way of reporting
since this would facilitate meaningful comparisons, i.e. using the
system for neurosurgical patients recently described [36].
Our study has several limitations. The patients included
represent an unsystematic selection that may not be representative
for the entire population of patients with glioblastoma. We believe
the lost-to follow-up rate of 9% is low. How these lost-to-follow-
Figure 2. Survival curves for the independent predictors presented in Table 3.
doi:10.1371/journal.pone.0028592.g002
Table 3. Cox multivariate regression.
a
HR univariate P-value
HR
Multivariate P-value 95% CI for multivariate HR
Lower Upper
Age 1.04 0.023 1.00 0.990 0.97 1.03
EOR 0.99 0.176 0.99 0.403 0.97 1.00
Radiotherapy 0.12 ,0.001 0.26 0.030 0.08 0.88
Temozolomide 0.20 ,0.001 0.30 0.019 0.11 0.82
KPS preoperative 0.98 0.083 0.99 0.325 0.96 1.01
HRQOL deterioration 2.11 0.022 2.02 0.045 1.02 4.00
All variables included in the model are presented both for univariate and multivariate analyses. Radiotherapy, use of temozolomide and deterioration in quality of life 6
weeks after surgery were independently associated with overall survival.
aEOR, extent of resection; KPS, Karnofsky Performance Status; HRQOL, health related quality of life; HR, hazard ratio; CI, confidence interval; p,0.05 is considered
significant.
doi:10.1371/journal.pone.0028592.t003
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three were dead or in a terminal condition, it is reasonable to
believe their HRQOL had deteriorated as well and further
strengthened the association. Adjuvant treatment (yes/no) was
included in the Cox regression model in spite of the risk of
survivorship effect overestimating the actual effect of the
intervention. A case-mix with 37.7% reoperated patients where
most had already received adjuvant treatment could possibly lead
to underestimation of the effect of adjuvant treatment. Although
the effect of lost HRQOL seems independent of given adjuvant
treatment, details of treatment protocols were not studied. We
therefore advise to interpret the effects of adjuvant therapy in this
study with some caution. Results from the ad-hoc analyses for
primary operations and reoperations separately, as requested in
the review process, may likely be due to type II errors and should
not alter the interpretation of the study. They suggest that the
findings in this study may be more representative for primary
operations than for reoperations, but this finding needs to be
verified in a larger study. Finally, the statistical method used in
creating a dichotomous variable (worse HRQOL: yes/no) from a
single variable is associated with an increase in false positive
findings [33]. However the cut-off chosen is not created on the
basis of finding the ‘‘optimal’’ cut-off, but out of logic and what we
thought would be of clinical relevance. Another important
statistical culprit is the floor-ceiling effect since patients in a good
preoperative condition can only become worse and vice versa.
Conclusion
Balancing risks with potential survival benefit and clinical
improvement is the key in surgical treatment of patients with
glioblastoma. Resection grades, overall survival, and PFS are
much used outcome parameters in surgical research, but they offer
no information on quality of survival. In this study we have
demonstrated that early deterioration in HRQOL after surgery is
independently and markedly associated with impaired survival.
Deterioration in patient reported HRQOL after surgery is a
meaningful outcome in surgical neuro-oncology as HRQOL
reflects the burden of symptoms, the treatment hazards and is
linked to survival.
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